StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Thursday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $0.26 on Thursday. The company has a market capitalization of $3.18 million, a P/E ratio of -0.04 and a beta of 0.85. Oragenics has a 52-week low of $0.24 and a 52-week high of $3.43. The company’s 50 day moving average price is $0.29 and its 200-day moving average price is $0.34.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.